Rani Therapeutics Holdings, Inc.(RANI)

$0.84—Stale · unknown old

Chart

Rani Therapeutics Holdings, Inc.(RANI)

NASDAQ • Last print unknown ago

$0.84—Stale · unknown old

Chart Studio

RANI(RANI)

RANI

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.05

Nov 5, 2026

Revenue Estimate

$1M

Analyst Sentiment

Wall St. Consensus

Buy

7 analysts·Limited coverage

Score

7 Buy (100%)0 Hold (0%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

7100%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$9.00

+971.4%

Consensus

$10.00

+1090.5%

Bull

$28.00

+3233.3%

12-Month Target Range7 analysts

$9.00$10.00$28.00

Current $0.84Consensus

Current Price

$0.84

Upside to Consensus

$9.16

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+5.93%

EPS—

FY2028

Rev+109.69%

EPS—

FY2029

Rev+8.45%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$6M	$7M	$14M	$15M	$46M
Low	$5M	$5M	$10M	$11M	$33M
High	$7M	$8M	$16M	$18M	$53M
EBITDA Avg	$-6M	$-7M	$-6M	$-7M	$-858,203
Low	$-9M	$-10M	$-8M	$-10M	$-2M
High	$-2M	$-3M	$-4M	$-3M	$2M
EBIT Avg	$-6M	$-7M	$-7M	$-8M	$-3M
Low	$-10M	$-11M	$-9M	$-11M	$-4M
High	$-3M	$-4M	$-5M	$-4M	$-153,048
Net Income Avg	$-11M	$-12M	$-11M	$-13M	$-7M
Low	$-14M	$-15M	$-13M	$-15M	$-8M
High	$-7M	$-8M	$-9M	$-8M	$-4M
EPS Avg	$-0.17	$-0.19	$-0.17	$-0.19	$-0.10
Low	$-0.21	$-0.23	$-0.20	$-0.23	$-0.13
High	$-0.11	$-0.12	$-0.14	$-0.12	$-0.07
Analysts (Rev / EPS)	3 / 2	3 / 2	4 / 3	2 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$1M	$2M	$5M	$5M	$5M	$5M
Low	$1M	$2M	$5M	$5M	$5M	$5M
High	$1M	$2M	$5M	$5M	$5M	$5M
EBITDA Avg	$-9M	$-9M	$-9M	$-9M	$-9M	$-9M
Low	$-9M	$-9M	$-9M	$-9M	$-9M	$-9M
High	$-9M	$-9M	$-9M	$-9M	$-9M	$-9M
EBIT Avg	$-9M	$-9M	$-9M	$-9M	$-9M	$-9M
Low	$-9M	$-9M	$-9M	$-9M	$-9M	$-9M
High	$-9M	$-9M	$-9M	$-9M	$-9M	$-9M
Net Income Avg	$-9M	$-9M	$-9M	$-9M	$-9M	$-9M
Low	$-9M	$-9M	$-9M	$-9M	$-9M	$-9M
High	$-9M	$-9M	$-9M	$-9M	$-9M	$-9M
EPS Avg	$-0.05	$-0.05	$-0.05	$-0.05	$-0.05	$-0.05
Low	$-0.05	$-0.05	$-0.05	$-0.05	$-0.05	$-0.05
High	$-0.05	$-0.05	$-0.05	$-0.05	$-0.05	$-0.05
Analysts (Rev / EPS)	2 / 2	2 / 2	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Jun 24, 2024Stifel Nicolaus

Stifel Reiterates Buy Rating on Rani Therapeutics Holdsing s (RANI)

Target:$10.00

+143.3%from $4.11

Mar 27, 2024Canaccord Genuity

Rani Therapeutics Holdsing s (RANI) PT Lowered to $9 at Canaccord Genuity on 'pushed back projected launch of RT-102'

Target:$9.00

+183.0%from $3.18

Jun 13, 2022Wedbush

Rani Therapeutics initiated with an Outperform at Wedbush

Target:$28.00

+197.9%from $9.40

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance